Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Key facts

Sponsor

Sutro Biopharma, Inc.

Principal Investigator

Craig Berman, MD

Sutro Biopharma

Intervention

Luveltamab tazevibulin(drug)

Enrollment

24 enrolled

Eligibility

12 years · All sexes

Timeline

2024 – 2025

Study locations (30)

• Childrens Hospital of Alabama, Birmingham, Alabama, United States
• Childrens Hospital of Los Angeles, Los Angeles, California, United States
• Lucile Packard Childrens Hospital-Stanford, Palo Alto, California, United States
• Children's Hospital of Colorado, Aurora, Colorado, United States
• Childrens National Hospital, Washington D.C., District of Columbia, United States
• Children's Hospital of Atlanta-Emory, Atlanta, Georgia, United States
• Ann & Robert H. Lurie Childrens Hospital, Chicago, Illinois, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• University of Minnesota-Masonic Cancer Center, Minneapolis, Minnesota, United States
• Children's Mercy Hospital, Kansas City, Missouri, United States
• Washington University-School of Medicine, St Louis, Missouri, United States
• Columbia University Irving Medical Center, New York, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
• Nationwide Children's Hospital, Columbus, Ohio, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Children's Oncology Group · Innovative Therapies For Children with Cancer Consortium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →